The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AILERON THERAPEUTICS INC COM 00887A105 740 517,558 SH   SOLE   517,558 0 0
APELLIS PHARMACEUTICALS INC COM 03753U106 47,843 1,114,962 SH   SOLE   1,114,962 0 0
ATEA PHARMACEUTICALS INC COM 04683R106 126,546 2,049,331 SH   SOLE   2,049,331 0 0
BELLICUM PHARMACEUTICALS INC COM NEW 079481404 96 25,651 SH   SOLE   25,651 0 0
CLEARSIDE BIOMEDICAL INC COM 185063104 1,960 793,555 SH   SOLE   793,555 0 0
KEZAR LIFE SCIENCES INC COM 49372L100 768 128,916 SH   SOLE   128,916 0 0
KYMERA THERAPEUTICS INC COM 501575104 24,834 639,059 SH   SOLE   639,059 0 0
MOLECULAR TEMPLATES INC COM 608550109 2,585 204,809 SH   SOLE   204,809 0 0
RAPT THERAPEUTICS INC COM 75382E109 2,409 108,503 SH   SOLE   108,503 0 0
SEER INC COM CL A 81578P106 53,340 1,066,375 SH   SOLE   1,066,375 0 0
SUTRO BIOPHARMA COM 869367102 3,983 175,000 SH   SOLE   175,000 0 0